{
    "root": "2cf172b2-a082-0637-e063-6394a90a2001",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tobramycin",
    "value": "20250301",
    "ingredients": [
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SULFURIC ACID",
            "code": "O40UQP6WCF",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26836"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "TOBRAMYCIN",
            "code": "VZ8RRZ51VK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28864"
        }
    ],
    "indications": {
        "text": "tobramycin inhalation solution indicated management cystic fibrosis adults pediatric patients 6 years age older pseudomonas aeruginosa . safety efficacy demonstrated patients age 6 years , patients forced expiratory volume 1 second ( fev 1 ) < 25 % > 75 % predicted , patients colonized burkholderia cepacia [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "cystic fibrosis (DOID:1485)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1485"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "cystic fibrosis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_586"
            }
        ]
    },
    "contraindications": {
        "text": "oral inhalation . ( 2.1 ) recommended adults pediatric patients 6 years age older one single-dose ampule ( 300 mg ) twice daily oral inhalation alternating periods 28 days , followed 28 days . ( 2.1 ) adjusted weight . ( 2.1 ) take doses close 12 hours apart possible ; less 6 hours apart . ( 2.1 ) administer 300 mg dose inhalation using hand-held pari lc plus \u00ae reusable nebulizer devilbiss \u00ae pulmo-aide \u00ae compressor . ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "tobramycin inhalation solution contraindicated patients known hypersensitivity aminoglycoside .",
    "indications_original": "Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with\n \n  Pseudomonas aeruginosa.\n\n \n                  Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV\n \n  1) <25% or >75% predicted, or patients colonized with\n \n  Burkholderia cepacia [see Clinical Studies (\n  \n   14)].",
    "contraindications_original": "For oral inhalation only. ( 2.1 ) The recommended dosage for adults and pediatric patients 6 years of age and older is one single-dose ampule (300 mg) twice daily by oral inhalation in alternating periods of 28 days on drug, followed by 28 days off drug. ( 2.1 ) Dosage is not adjusted by weight. ( 2.1 ) Take doses as close to 12 hours apart as possible; but not less than 6 hours apart. ( 2.1 ) Administer each 300 mg dose by inhalation using a hand-held PARI LC PLUS \u00ae Reusable Nebulizer with a DeVilbiss \u00ae Pulmo-Aide \u00ae compressor. ( 2.2 )",
    "adverseReactions_original": "Tobramycin inhalation solution is contraindicated in patients with a known hypersensitivity to any aminoglycoside.",
    "drug": [
        {
            "name": "Tobramycin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28864"
        }
    ]
}